Osteoporosis

After a reexamination procedure, a European Medicines Agency committee announced a positive opinion recommending marketing authorization for romosozumab for the treatment of severe osteoporosis in postmenopausal women at high risk for fracture with no history of myocardial infarction or stroke, according to a press release from Amgen and UCB.

SAN DIEGO — Taking a ‘holiday’ from many osteoporosis drugs can frequently negate gains in bone density, according to a presentation at the 2019 Congress of Clinical Rheumatology West.

Only 1 in 10 men and fewer than 2 in 10 women who did not receive osteoporosis therapy at the time of a fracture were prescribed adequate treatment during follow-up, increasing secondary fracture risks for those left untreated, according to an analysis of data from Austria published in Bone.

The FDA on Monday approved an osteoporosis medication — PF708 — developed by Pfenex under the 505(b)(2) regulatory pathway as a follow-on biologic to teriparatide injection, according to a press release from the company.

Older adults who sustain a hip or vertebral fracture should be appropriately evaluated and treated for osteoporosis to reduce the risk for secondary fracture, with clinicians utilizing fracture liaison services and offering pharmacotherapy, according to a consensus statement published in the Journal of Bone and Mineral Research.

Among a cohort of postmenopausal women randomly assigned to romosozumab or alendronate, larger improvements in bone mineral density and bone strength in the lumbar spine were observed for those taking romosozumab, according to findings presented at the American Society of Bone and Mineral Research annual meeting.

Postmenopausal women who took denosumab for a year did experienced no significant decrease in bone mineral density after switching to alendronate, according to findings presented at the American Society of Bone and Mineral Research annual meeting.

Researchers identified a link between the presence and severity of nonalcoholic fatty liver disease in children with reduced whole-body bone mineral density, according to results of a systematic review and meta-analysis.

Approximately 11% of middle-aged adults in the United States have osteoporosis, with the cost for care rising by nearly $50 billion over more than a decade, according to study data presented at the American Society for Bone and Mineral Research annual meeting.

Healthy, middle-aged adults without osteoporosis assigned to a high-dose daily vitamin D liquid drop had reduced bone mineral density at 3 years when compared with similar adults assigned to a daily low-dose supplement, according to findings published in JAMA.